Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).
1,2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.
GCs decrease the activity of glycolytic enzymes 3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo. 4 This led us to investigate whether co-administration of 2-deoxyglucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only, 5 might potentiate the apoptotic effect of GC. Table S1 ), and reduced proliferation rates in the first 48 h by about 50% in both systems (data not shown). The two cell lines differed in their sensitivity to individual and combined treatment with 2-DG and DEX; 697/ EU-3 cells showed a higher sensitivity to sole 2-DG treatment with respect to apoptosis. The lowest effective doses of 2-DG were 1 and 3 mM for 697/EU-3 and CEM-C7H2 cells, respectively (equaling 10 and 30% of glucose in the medium). Lower concentrations of 2-DG failed to exert a synergistic effect. Berenbaum factors 0.43 and 0.35 (see Supplementary Information) implied a strong synergism of DEX and 2-DG in 697/EU-3 as well as CEM-C7H2 cells. Comparing apoptotic rates induced by the combined treatment to the sum of the apoptotic rates of the single substances (additive effect Figures 1a and b) further supported a strong synergistic effect.
In GC-resistant derivatives of CEM-C7H2 and 697/EU-3, 2-DG exerted a considerable proapoptotic effect, more pronounced in combination with 100 nM DEX, and inhibited proliferation (Supplementary Figure S1) . Resistant clones exhibited stronger 2-DG sensitivity to apoptosis than the parental GC-sensitive clones. This might be due to higher glycolytic activity of GC-resistant cells, 6 which was also suggested in patients classified as GCs poor responders. 3 2-DG had no significant impact on cell viability and DEX-induced apoptosis in primary resting lymphocytes or CD3/CD28-activated lymphocytes (Supplementary Table S2 ), suggesting a cancer-specific effect. Most cancer cells depend on glycolysis and might be generally more sensitive to the combination of an apoptosis inducer with a glycolysis inhibitor. Therefore, we combined 2-DG with vincristine, gemcitabine, reexpression of p53 or an antibody against Fas. 2-DG did not potentiate the apoptotic effect or accelerate the kinetics of apoptosis, despite 48 h of 2-DG and 1 nM vincristine treatment (Supplementary  Table S3 ).
On cellular uptake through glucose transporters, 2-DG is immediately phosphorylated by the enzyme hexokinase (HK) to 2-deoxy-glucose-6-phosphate (2-DG-P). Accumulating 2-DG-P inhibits HK activity and potentially induces the release of HK from the outer mitochondrial membrane, thereby depressing energy metabolism and increasing mitochondrial susceptibility to damage. 7 In both GC-sensitive ALL cell lines, 2-DG-P (12/24 h 151/178 nmol/mg protein in CEM-C7H2 cells, 12/24 h 142/146 nmol/mg protein in 697/EU-3 cells) accumulated after treatment with 3 mM and 1 mM 2-DG, respectively. The levels of glucose-6-phosphate, in comparison, ranged from 5 to 20 nmol/mg protein.
Treatment with DEX, 2-DG or the combination of the two agents induced a decrease in glycolysis as evidenced by markedly reduced lactate production ( Figures 2a and b) ; 2-DG revealed a stronger effect than that of DEX. A decrease in lactate dehydrogenase activity, detected only under combination treatment (CEM-C7H2: 12%; 697/EU-3: 20%), was not sufficient to explain the strong decrease in lactate production. In CEM-C7H2, the combined treatment led to a significant reduction in glucose uptake within the first 12 h (Figure 2c ), whereas treatments with either substance exerted a delayed effect. In 697/EU-3 cells, either treatment resulted in a persisting inhibition of glucose uptake ( Figure 2d ). A downregulation of the glucose transporter 1 (GLUT1) by 50% at the gene expression level was detected in the CEM-C7H2 cells as early as 3 h after stimulation, whereas in 697/EU-3 cells only a slight reduction was observed. In contrast, GLUT3 and GLUT14 expression were not regulated in both the cell lines (data not shown). We hypothesize that the uptake and usage of glucose are downregulated due to product inhibition by high intracellular levels of 2-DG-P.
Furthermore, a reduced cellular HK2 content, the predominant HK in cancer cells, was observed in both model systems. In CEM-C7H2 cells, reduced mitochondrial bound HK2 protein levels were detected after 12-h treatment with either 100 nM DEX or 3 mM 2-DG, and even more pronounced in the combination thereof (Figures 3a) . In the cytosolic fraction, no alterations were observed (Figure 3a) . This suggested that levels of HK2 decreased due to both its detachment from the outer mitochondrial membrane and downregulation of its expression. The detected detachment is in agreement with the observation that DEX enhances 2-DG-P accumulation in CEM-C7H2 cells within the first 12 h. Reverse transcriptase-PCR revealed a strong decrease in HK2 mRNA expression in CEM-C7H2 cells treated for 3 h with 100 nM DEX and 3 mM 2-DG (Supplementary Figure  S2) . The downregulation of HK2 was even stronger after 12 h (83%) and persisted until cell death. In comparison, in 697/EU-3 cells, an increasing reduction in HK2 at the protein level was observed over time (Figure 3b ), although mRNA levels were only reduced after 12 h (Supplementary Figure S2) . As it proved impossible to separate the mitochondrial from the cytosolic fraction in 697/EU-3 cells without leakage of mitochondrial HK2 into the cytosol, only total cellular HK2 protein content was determined. Expression of the HK1 gene remained unchanged until cell death in all the cell lines tested (data not shown).
A decreased glycolytic activity may be compensated by increased mitochondrial oxidative phosphorylation. Alternatively, it may disturb mitochondrial respiration due to substrate limitation. We observed an early increase in oxygen uptake by sole 2-DG treatment, which was inhibited by DEX (Supplementary Figure S3 ). After 24 h, combination treatment resulted in a 35% reduction in mitochondrial endogenous respiration, 12 h before the effects of sole DEX treatment in both model systems (Supplementary Table S4 ). Under all the treatments, stimulation of the respiratory system by uncoupling, using endogenous substrates, increased oxygen consumption in controls and treated cells by the same factor (uncoupling control ratio; Supplementary Table S4) . Hence, mitochondrial substrate supply was not limited. Mitochondrial oxygen consumption was still coupled to ATP production, shown by inhibited respiration after administration of the ATP synthase inhibitor oligomycin. The 35% reduction in oxygen consumption was not the result of reduced mitochondrial content, because activity of the matrix marker enzyme citrate synthase was preserved except for sole DEX treatment after 36 h (Supplementary Table S4 ). Together with a previous study on the use of meta-iodobenzylguanidine, which inhibits both complex I and III of the respiratory chain, the present data underscore the potential of targeting mitochondrial activity as a means of both sensitizing ALL cells to GCs and of overcoming resistance to GCs. 8 Downregulation of the two ATP-producing pathways, glycolysis and mitochondrial respiration entails a decrease in cellular ATP production. Reduced ATP levels act as a general cellular stress signal, leading to the onset of apoptosis. 9 In both GCsensitive ALL cell lines, the combination treatment reduced ATP levels strongly within 12 h ( Table 1 ). The decrease in ATP levels occurred before cell death and was not a consequence of apoptosis. If reduced ATP levels were to initiate apoptosis, restoring ATP levels should inhibit apoptosis. To this end, we added 6 mM pyruvate to the different treatments. In our B-ALL model, the administration of 6 mM pyruvate reverted the 2-DGinduced decrease in ATP levels (Supplementary Figure S4A) , reduced the apoptotic rate under sole 2-DG treatment (Supplementary Figure S4B ) and completely abolished the synergistic effect on cell death induction (Supplementary Figure S4C) . The decrease in proliferation rate of 2-DG-treated cells was diminished, albeit not to control rates. Pyruvate enhanced oxygen consumption under 2-DG treatment in both cell lines (Supplementary Figure S3) . Nevertheless, in CEM-C7H2 cells, pyruvate failed to increase ATP concentration to the level of DEX-treated cells, and did not abolish the acceleration of GCtriggered apoptosis by 2-DG. As pyruvate can also act as a scavenger of ROS, which are reportedly involved in GC-induced cell death, ROS production was determined. In this study, however, no increased ROS production could be detected (data not shown).
Both ALL model systems shared substantial treatment-related alterations in energy metabolism induced by 2-DG and DEX individually, and significantly enforced by their combination. We further observed an accumulation of 2-deoxyphosphogluconate and orotate (data not shown), indicating that 2-DG does not only affect glycolysis, but also the pentose phosphate pathway. The synergistic effect of 2-DG on GC-induced apoptosis might prove beneficial in the therapy of childhood ALL, as a reduction in the effective GC concentration might diminish GC-related side effects. This study seems to hold sufficient promise to justify further ex vivo and animal studies on the potential of the treatment of ALL with a combination of GCs and 2-DG. Letters to the Editor
